The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.
D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D001419:Bacteria / Q000187:drug effects; D001798:Blood Proteins / Q000378:metabolism; D002939:Ciprofloxacin; D015365:Enoxacin; D005461:Fluorine / Q000009:adverse effects / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007668:Kidney / Q000378:metabolism; D007700:Kinetics; D009287:Naphthyridines / Q000009:adverse effects / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use; D009643:Norfloxacin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use; D015242:Ofloxacin; D010078:Oxazines / Q000009:adverse effects / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use; D015366:Pefloxacin; D011485:Protein Binding; D011804:Quinolines / Q000009:adverse effects / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use; D014552:Urinary Tract Infections / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D001798:Blood Proteins; D009287:Naphthyridines; D010078:Oxazines; D011804:Quinolines; D005461:Fluorine; D015366:Pefloxacin; D015365:Enoxacin; D002939:Ciprofloxacin; D015242:Ofloxacin; D009643:Norfloxacin